Literature DB >> 16627617

TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity.

Qian Yang1, Ken Inoki, Eunjung Kim, Kun-Liang Guan.   

Abstract

Target of rapamycin (TOR) plays a central role in cell growth regulation by integrating signals from growth factors, nutrients, and cellular energy levels. TOR forms two distinct physical and functional complexes, termed TOR complex 1 (TORC1) and TOR complex 2 (TORC2). TORC1, which is sensitive to rapamycin, regulates translation and cell growth, whereas TORC2, which is insensitive to rapamycin, regulates cell morphology and cell growth. The Ras homology enriched in brain (Rheb) small GTPase is known to be a key upstream activator of TORC1, although the mechanism of Rheb in TORC1 activation remains to be determined. However, the function of Rheb in the TORC2 regulation has not been elucidated. By measuring Akt and S6K phosphorylation as a functional assay for TORC1 and -2, here, we report that dRheb has an inhibitory effect on dTORC2 activity in Drosophila S2 cells. This negative effect of dRheb on dTORC2 is possibly due to a feedback mechanism involving dTORC1 and dS6K. We also observed that Rheb does not activate TORC2 in human embryonic kidney 293 cells, although it potently stimulates TORC1. Furthermore, tuberous sclerosis complex 1 (TSC1) and TSC2, which are negative regulators of Rheb, have negative and positive effects on TORC1 and -2, respectively. Our observations suggest that TSC1/2 and Rheb have different effects on the activity of TORC1 and -2, further supporting the complexity of TOR regulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627617      PMCID: PMC1458976          DOI: 10.1073/pnas.0602282103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  RNA interference of gene expression (RNAi) in cultured Drosophila cells.

Authors:  C A Worby; N Simonson-Leff; J E Dixon
Journal:  Sci STKE       Date:  2001-08-14

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  In vivo role of the phosphate groove of PDK1 defined by knockin mutation.

Authors:  Barry J Collins; Maria Deak; Vicky Murray-Tait; Kate G Storey; Dario R Alessi
Journal:  J Cell Sci       Date:  2005-10-11       Impact factor: 5.285

4.  Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization.

Authors:  Yoshiaki Kamada; Yuko Fujioka; Nobuo N Suzuki; Fuyuhiko Inagaki; Stephan Wullschleger; Robbie Loewith; Michael N Hall; Yoshinori Ohsumi
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

5.  dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1.

Authors:  Thomas Radimerski; Jacques Montagne; Felix Rintelen; Hugo Stocker; Jeroen van der Kaay; C Peter Downes; Ernst Hafen; George Thomas
Journal:  Nat Cell Biol       Date:  2002-03       Impact factor: 28.824

6.  Rheb binds and regulates the mTOR kinase.

Authors:  Xiaomeng Long; Yenshou Lin; Sara Ortiz-Vega; Kazuyoshi Yonezawa; Joseph Avruch
Journal:  Curr Biol       Date:  2005-04-26       Impact factor: 10.834

7.  Identification of a conserved motif required for mTOR signaling.

Authors:  Stefanie S Schalm; John Blenis
Journal:  Curr Biol       Date:  2002-04-16       Impact factor: 10.834

Review 8.  Ten years of protein kinase B signalling: a hard Akt to follow.

Authors:  D P Brazil; B A Hemmings
Journal:  Trends Biochem Sci       Date:  2001-11       Impact factor: 13.807

9.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

10.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.

Authors:  E H Walker; M E Pacold; O Perisic; L Stephens; P T Hawkins; M P Wymann; R L Williams
Journal:  Mol Cell       Date:  2000-10       Impact factor: 17.970

View more
  80 in total

1.  PI3K-mTORC1 attenuates stress response by inhibiting cap-independent Hsp70 translation.

Authors:  Jun Sun; Crystal S Conn; Yan Han; Vincent Yeung; Shu-Bing Qian
Journal:  J Biol Chem       Date:  2010-12-22       Impact factor: 5.157

2.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

3.  Specific killing of Rb mutant cancer cells by inactivating TSC2.

Authors:  Binghui Li; Gabriel M Gordon; Charles H Du; Jinhua Xu; Wei Du
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

4.  Targeting Rb inactivation in cancers by synthetic lethality.

Authors:  Gabriel M Gordon; Wei Du
Journal:  Am J Cancer Res       Date:  2011-06-30       Impact factor: 6.166

Review 5.  Regulation of mTORC1 by PI3K signaling.

Authors:  Christian C Dibble; Lewis C Cantley
Journal:  Trends Cell Biol       Date:  2015-07-06       Impact factor: 20.808

6.  Opposite effects of tor1 and tor2 on nitrogen starvation responses in fission yeast.

Authors:  Ronit Weisman; Irina Roitburg; Miriam Schonbrun; Rona Harari; Martin Kupiec
Journal:  Genetics       Date:  2006-12-18       Impact factor: 4.562

7.  Rapamycin and mTOR kinase inhibitors.

Authors:  Lisa M Ballou; Richard Z Lin
Journal:  J Chem Biol       Date:  2008-05-15

8.  Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin.

Authors:  Itzamarie Chévere-Torres; Jordan M Maki; Emanuela Santini; Eric Klann
Journal:  Neurobiol Dis       Date:  2011-07-30       Impact factor: 5.996

9.  Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein.

Authors:  Tatsuhiro Sato; Akio Nakashima; Lea Guo; Fuyuhiko Tamanoi
Journal:  J Biol Chem       Date:  2009-03-19       Impact factor: 5.157

10.  Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Authors:  Andre Cassell; Maria L Freilino; Jessica Lee; Sharon Barr; Lin Wang; Mary C Panahandeh; Sufi M Thomas; Jennifer R Grandis
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.